LivaNova (NASDAQ:LIVN) Shares Up 4% – What’s Next?

LivaNova PLC (NASDAQ:LIVN) shares rose 4% during mid-day trading on Monday . The stock traded as high as $49.18 and last traded at $49.33. Approximately 235,591 shares traded hands during trading, a decline of 47% from the average daily volume of 442,709 shares. The stock had previously closed at $47.44.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Needham & Company LLC reiterated a “buy” rating and issued a $75.00 price objective on shares of LivaNova in a research report on Tuesday, January 28th. StockNews.com upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a report on Friday, February 14th. Robert W. Baird upped their target price on shares of LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Finally, Mizuho decreased their price objective on LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday, October 31st. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $69.17.

LivaNova Stock Performance

The stock has a 50-day moving average price of $47.95 and a 200 day moving average price of $49.60. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The company has a market cap of $2.69 billion, a price-to-earnings ratio of 118.22 and a beta of 1.00.

Insider Transactions at LivaNova

In related news, Director Francesco Bianchi sold 1,250 shares of the stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total transaction of $63,737.50. Following the completion of the transaction, the director now directly owns 7,522 shares in the company, valued at approximately $383,546.78. This trade represents a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.27% of the stock is owned by insiders.

Hedge Funds Weigh In On LivaNova

A number of large investors have recently bought and sold shares of the company. Russell Investments Group Ltd. boosted its holdings in LivaNova by 17.1% during the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock worth $70,000 after purchasing an additional 219 shares during the last quarter. Summit Investment Advisors Inc. raised its holdings in LivaNova by 1.7% during the fourth quarter. Summit Investment Advisors Inc. now owns 16,846 shares of the company’s stock worth $780,000 after acquiring an additional 289 shares in the last quarter. Atria Investments Inc grew its stake in LivaNova by 6.2% in the third quarter. Atria Investments Inc now owns 5,653 shares of the company’s stock valued at $297,000 after purchasing an additional 331 shares in the last quarter. State of Alaska Department of Revenue raised its stake in shares of LivaNova by 7.3% during the 3rd quarter. State of Alaska Department of Revenue now owns 6,246 shares of the company’s stock worth $328,000 after purchasing an additional 425 shares in the last quarter. Finally, Xponance Inc. boosted its holdings in shares of LivaNova by 6.1% in the 4th quarter. Xponance Inc. now owns 7,762 shares of the company’s stock valued at $359,000 after buying an additional 445 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.